Fujifilm Holdings Corporation (FUJIY):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Fujifilm Holdings Corporation (FUJIY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11513
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Fujifilm Holdings Corp (Fujifilm) sales and manufactures imaging systems and document solution equipment. The company’s major products are color films, color paper and chemicals, photofinishing equipment, electronic imaging and optical devices, TV camera lenses, security lenses, healthcare products, graphic systems, flat panel display materials, recording media and industrial products. It also offers document solutions such as office products, office printers, and allied production services and global services. The company serves individual consumers and business enterprises. Its two major operating subsidiaries include FUJIFILM Corporation and Fuji Xerox Co. Ltd. The company conducts business operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Fujifilm is headquartered in Tokyo, Japan.

Fujifilm Holdings Corporation (FUJIY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Fujifilm Holdings Corporation, Medical Devices Deals, 2012 to YTD 2018 11
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deal Details 15
Partnerships 15
FUJIFILM Diosynth Biotechnologies and Centre for Process Innovation Enter into Collaboration Agreement 15
Fujifilm to Enter into Partnership with Zhejiang Hisun Pharma, China-Japan Friendship Clinic and National Engineering Research Center 16
Fujifilm and Takeda Pharma Enter into Agreement 17
RegenxBio Enters into Agreement with Fujifilm Diosynth Biotechnologies 18
EdiGene Enters into Research Agreement with Fujifilm 19
CanBas Enters into Research Agreement with Fujifilm 20
FunPep Enters into Research Agreement with Fujifilm 21
China Resources Holdings Enter into Agreement with Fujifilm Holdings 22
China Resources Pharmaceutical Enters into Agreement with Fujifilm 23
AdAlta Enters into Agreement with FujiFilm Diosynth 24
Cynata Therapeutics to Enter into Co-Development Agreement with Fujifilm 25
Fujifilm Diosynth Biotech Partners with Merck 26
Bioaster Partners with Fujifilm 27
Fujifilm Enters into Co-Marketing Agreement with Shenzhen Main Luck Pharma 28
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 29
Masthercell Forms Joint Venture with Kalon 30
Fujifilm Diosynth Biotech Enters Into Agreement With Piramal Healthcare To Develop Antibody Drug Conjugates 31
Yokogawa Electric Enters Into Co-Marketing Agreement With Wako Pure Chemical Industries For CellVoyager CV7000 32
FUJIFILM Forms Joint Venture With Kyowa Hakko Kirin 33
Licensing Agreements 35
FUJIFILM Cellular Dynamics Enters into Licensing Agreement with University of California Irvine 35
TR-Pharm Enters into Licensing Agreement with Toyama Chemical 36
Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 37
Cempra Enters Into Licensing And Development Agreement With Toyama Chemical For Solithromycin 38
Zhejiang Hisun Pharma Enters into Licensing Agreement with Fujifilm 40
Equity Offering 41
Suono Bio Raises Funds through Private Placement 41
Fujifilm to Invest USD3.4 Million in Cyfuse Biomedical 42
Fujifilm Invests USD0.3 Million in Japan Biomedical 43
Fujifilm Invests USD1.5 Million in Regcell 44
Asset Transactions 45
Eisai to Acquire Rights of Kolbet from Toyoma Chemical and Taisho Pharma 45
Acquisition 46
Fujifilm Holdings to Acquire Additional 34% Stake in Toyama Chemical 46
Fujifilm Acquires 11.7% Stake in EdiGene 47
Fujifilm Acquires 6% stake in NC Medical Research for USD3.8 Million 48
Fujifilm Acquires Cellular Dynamics for USD238 Million in Tender Offer 49
Fujifilm Diosynth Biotech Acquires 49% Stake in Kalon Biotherapeutics 51
Fujifilm Holdings Corporation – Key Competitors 52
Fujifilm Holdings Corporation – Key Employees 53
Fujifilm Holdings Corporation – Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Recent Developments 56
Product News 56
11/13/2018: Research results for FF-10850, a novel liposome drug candidate for improvement of pharmacological efficacy through selective delivery of anti-cancer agent to tumors 56
02/22/2018: New Manufacturing Facility to be Built at Toyama Chemical, a Fujifilm Company 58
Clinical Trials 59
Aug 30, 2017: Clinical Trials of Anti-cancer Agent FF-10832 to start in the US for Advanced Solid Tumors 59
Aug 08, 2017: Fujifilm initiates a Phase I clinical trial of Anti-Cancer Drug FF-10101 in the United States in patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Fujifilm Holdings Corporation, Deals By Therapy Area, 2012 to YTD 2018 10
Fujifilm Holdings Corporation, Medical Devices Deals, 2012 to YTD 2018 11
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
FUJIFILM Diosynth Biotechnologies and Centre for Process Innovation Enter into Collaboration Agreement 15
Fujifilm to Enter into Partnership with Zhejiang Hisun Pharma, China-Japan Friendship Clinic and National Engineering Research Center 16
Fujifilm and Takeda Pharma Enter into Agreement 17
RegenxBio Enters into Agreement with Fujifilm Diosynth Biotechnologies 18
EdiGene Enters into Research Agreement with Fujifilm 19
CanBas Enters into Research Agreement with Fujifilm 20
FunPep Enters into Research Agreement with Fujifilm 21
China Resources Holdings Enter into Agreement with Fujifilm Holdings 22
China Resources Pharmaceutical Enters into Agreement with Fujifilm 23
AdAlta Enters into Agreement with FujiFilm Diosynth 24
Cynata Therapeutics to Enter into Co-Development Agreement with Fujifilm 25
Fujifilm Diosynth Biotech Partners with Merck 26
Bioaster Partners with Fujifilm 27
Fujifilm Enters into Co-Marketing Agreement with Shenzhen Main Luck Pharma 28
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 29
Masthercell Forms Joint Venture with Kalon 30
Fujifilm Diosynth Biotech Enters Into Agreement With Piramal Healthcare To Develop Antibody Drug Conjugates 31
Yokogawa Electric Enters Into Co-Marketing Agreement With Wako Pure Chemical Industries For CellVoyager CV7000 32
FUJIFILM Forms Joint Venture With Kyowa Hakko Kirin 33
FUJIFILM Cellular Dynamics Enters into Licensing Agreement with University of California Irvine 35
TR-Pharm Enters into Licensing Agreement with Toyama Chemical 36
Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 37
Cempra Enters Into Licensing And Development Agreement With Toyama Chemical For Solithromycin 38
Zhejiang Hisun Pharma Enters into Licensing Agreement with Fujifilm 40
Suono Bio Raises Funds through Private Placement 41
Fujifilm to Invest USD3.4 Million in Cyfuse Biomedical 42
Fujifilm Invests USD0.3 Million in Japan Biomedical 43
Fujifilm Invests USD1.5 Million in Regcell 44
Eisai to Acquire Rights of Kolbet from Toyoma Chemical and Taisho Pharma 45
Fujifilm Holdings to Acquire Additional 34% Stake in Toyama Chemical 46
Fujifilm Acquires 11.7% Stake in EdiGene 47
Fujifilm Acquires 6% stake in NC Medical Research for USD3.8 Million 48
Fujifilm Acquires Cellular Dynamics for USD238 Million in Tender Offer 49
Fujifilm Diosynth Biotech Acquires 49% Stake in Kalon Biotherapeutics 51
Fujifilm Holdings Corporation, Key Competitors 52
Fujifilm Holdings Corporation, Key Employees 53
Fujifilm Holdings Corporation, Subsidiaries 54

List of Figures
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Fujifilm Holdings Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Fujifilm Holdings Corporation, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Fujifilm Holdings Corporation (FUJIY):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pental Limited (PTL):企業の財務・戦略的SWOT分析
    Pental Limited (PTL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Nymox Pharmaceutical Corp (NYMX):企業の財務・戦略的SWOT分析
    Nymox Pharmaceutical Corp (NYMX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Hokkaido Electric Power Co Inc (9509):企業の財務・戦略的SWOT分析
    Hokkaido Electric Power Co Inc (9509) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Acura Pharmaceuticals Inc (ACUR)-医療機器分野:企業M&A・提携分析
    Summary Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tamp …
  • Seres Therapeutics Inc (MCRB):企業の財務・戦略的SWOT分析
    Summary Seres Therapeutics Inc (Seres), is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company’ …
  • Toyo Engineering & Construction Sdn Bhd:企業の戦略的SWOT分析
    Toyo Engineering & Construction Sdn Bhd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Reliance Communications Limited:企業の戦略・SWOT・財務分析
    Reliance Communications Limited - Strategy, SWOT and Corporate Finance Report Summary Reliance Communications Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • EMC Insurance Group Inc.:企業の戦略・SWOT・財務情報
    EMC Insurance Group Inc. - Strategy, SWOT and Corporate Finance Report Summary EMC Insurance Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Celdara Medical LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Celdara Medical LLC (Celdara Medical) is a biotechnology company that helps transform academic innovations into medicines to cure serious diseases. It provides pipeline development services, and has a pipeline of anti-inflammatory therapeutics, latent HIV elimination, idiopathic pulmonary fi …
  • OMV Petrom SA (SNP):電力:M&Aディール及び事業提携情報
    Summary OMV Petrom SA (Petrom), a subsidiary of OMV AG, is an integrated energy company that explores for, develops and produces crude oil and natural gas. The company processes and refines crude oil and sells refined products. It conducts power generation and has considerable wind energy operations …
  • Telkom SA SOC Limited (TKG):企業の財務・戦略的SWOT分析
    Telkom SA SOC Limited (TKG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Huntsman Corp (HUN):企業の財務・戦略的SWOT分析
    Huntsman Corp (HUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Acorda Therapeutics Inc (ACOR)-製薬・医療分野:企業M&A・提携分析
    Summary Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. The company’s commercial products include Ampyra (dalfampridine), a treatment to improve walking in patients with multiple …
  • Finnair Oyj:企業のM&A・事業提携・投資動向
    Finnair Oyj - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Finnair Oyj Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • London North West Healthcare NHS Trust:企業の戦略的SWOT分析
    London North West Healthcare NHS Trust - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Nissin Foods Holdings Co Ltd (2897):企業の財務・戦略的SWOT分析
    Nissin Foods Holdings Co Ltd (2897) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Anacor Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Anacor Pharmaceuticals Inc (Anacor) is a biopharmaceutical company that discovers, develops and markets small molecule therapeutics based on its boron chemistry platform. The company’s marketed products include a topical solution which is an oxaborole antifungal that is used for the topical …
  • HepQuant Llc:製品パイプライン分析
    Summary Hepquant LLC (Hepquant) is a medical device company that provides diagnostic products. The company develops and markets products for measuring liver function. It offers products such as hepquant-stat, hepquant-shunt, and hepquant-flow. Hepquant’s hepquant-STAT is used in screening assay to i …
  • VentiRx Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary VentiRx Pharmaceuticals Inc (VentiRx) is a biopharmaceutical company that develops and commercializes drugs for the treatment of respiratory, autoimmune diseases and cancer. The company develops toll like receptor 8 agonist and antagonists for the treatment of cancer, respiratory and autoimm …
  • Interfor Corp:企業の戦略・SWOT・財務情報
    Interfor Corp - Strategy, SWOT and Corporate Finance Report Summary Interfor Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆